AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Beyfortus (nirsevimab by Quarter
Beyfortus (nirsevimab — direct product sales) — US product sales ($M) ($M)
AstraZeneca Beyfortus (nirsevimab: $38M in Q2 2026, down 47.9% from a year earlier.
Latest, Q2 2026
38
Period ended Jun 30, 2026
Change on a year earlier
-47.9%
73 in Q2 2025
History
13 quarters
Since Q2 2023
Sources
13
Documents cited below
Where the Q2 2026 figure comes from
“|| Beyfortus | | 47 | | ( 52 ) | | ( 52 ) | | 38 | | ( 49 ) | | - | | - | | - | | 8 | | ( 66 ) | | ( 67 ) | | 1 | | 34 | | 58”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Beyfortus (nirsevimab — direct product sales) — US product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 38 | -47.9% | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | 23 | -17.9% | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | 48 | -42.9% | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | 35 | -63.2% | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | 73 | +170.4% | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | 28 | +7.7% | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q4 2024 | Dec 31, 2024 | 84 | +61.5% | Form 6-K FY2024Q4 Earnings Release ↗ |
| Q3 2024 | Sep 30, 2024 | 95 | – | Form 6-K FY2024Q3 Earnings Release ↗ |
| Q2 2024 | Jun 30, 2024 | 27 | – | Form 6-K FY2024Q2 Earnings Release ↗ |
| Q1 2024 | Mar 31, 2024 | 26 | – | Form 6-K FY2024Q1 Earnings Release ↗ |
| Q4 2023 | Dec 31, 2023 | 52 | – | Form 6-K FY2023Q4 Earnings Release ↗ |
| Q3 2023 | Sep 30, 2023 | 0 | – | Form 6-K FY2023Q3 Earnings Release ↗ |
| Q2 2023 | Jun 30, 2023 | 0 | – | Form 6-K FY2023Q2 Earnings Release ↗ |
Breakdown
What makes up beyfortus (nirsevimab
Cite this data
StockData. (2026). AstraZeneca Beyfortus (nirsevimab ($M), quarterly Q2 2023–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-beyfortus-us
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.